RecruitingPhase 2NCT04775706

Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

Studying Short bowel syndrome

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Hanmi Pharmaceutical Company Limited
Intervention: HM15912 Active(drug)
Enrollment: 18 enrolled
Eligibility: 18 years · All sexes
Timeline: 2022 – 2028

Study locations (13)

Brigham & Women's Hospital, Boston, Massachusetts, United States
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
UZ Leuven, Leuven, Vlaams Brabant, Belgium
Rigshospitalet Department of Digestive Diseases, Transplantation and General Surgery Section for Intestinal Failure, Copenhagen, Denmark
Hopital Beaujon, Clichy, Clichy, France
Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
Les Hospices Civils de Lyon, Lyon, France
Centre Hospitalier Universitaire de Nice, Nice, France
Asklepios Klinik St. Georg, Hamburg, Hamburg, Germany
Universitätsklinikum Tübingen, Tübingen, Tübingen, Germany
Wojewodzki Specjalistyczny Szpital im. Mikołaja Pirogowa w Łodzi, Lodz, Łódź Voivodeship, Poland
Samsung Medical Center, Seoul, South Korea
Central Middlesex Hospital, London, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04775706 on ClinicalTrials.gov

Other trials for Short bowel syndrome

Additional recruiting or active studies for the same condition.

See all trials for Short bowel syndrome →

← Back to all trials